

Webinar Presentation 2nd quarter and 6 months of 2013

September 10, 2013






2nd Quarter

Sales in 2nd Quarter

Yet Another Record

- Sales worth more than 12 million lats (17 million euros), an increase by 13%
- About 2.3 million lats are sales by pharmacies, increase by 47%;
- Again, the best second quarter so far;
- 2nd and 3rd quarters traditionally lower than 1st and 4th due to seasonality.

Sales by Quarters Thsnd. LVL







Profit of 2nd Quarter

Record Despite Issues

- Preliminary at 1.67 million lats (2,3 million euros), an increase by 28%;
- Best Q2 ever;
- Negative Russian rouble fluctuations took about 0.4 m LVL from profit of Q2;

1 000

6 000 5 000 4 000 2 000

2009/ 3 3 2009/ 4 4 1 1 2010/ 2011/ 2011/ 2012/ 2012/ 2012/ 2012/ 2013/ 2013/ 2013/ 2013/ 2013/ 2013/ 2013/ 2013/ 2013/

Profit by Quarters




→LVL '000 ---EUR '000

Sales by Countries, Q2

The Netherlands Among Key Markets

- Good performance in all key markets, except Ukraine;
- Russia's share up to 42% from 38%, UK down to 6% from 11%;
- Particularly good performance in The Netherlands and Spain in Q2;






Sales by Products, Q2

2nd Tier Catching up

- Still a good diversity;
- Neiromidin down to 18%, with a good growth in total sales;
- Remantadin out of top 10, PASA in;
- Others reached 17%










6 months

Sales in 6 Months

It's a Record Again

- Sales worth 24.3 million lats (34.6 million euros), or 7% higher than last year;
- Of this bout 3.3 million lats are net sales by pharmacies;
- Again the best first six months so far;
- Achieved despite the fact that 4 out of 6 months Ukrainian sales were absent.

6 Months Sales, Thsnd.






Profit of 6 Months

Keeps Increasing

- Preliminary at 3.6 million lats (5.2 million euros);
- Q2 hit by rouble fluctuations;
- By 1,8% smaller than in 2012;
- Rouble fluctuations of Q1 and Q2 are levelling out;
- Yet again best so far;
- About a third of annual target met, best months are still to come.

Six Months Profit, Thsnd.






Growth Drivers: Products

It's About Even

- 9 out of 15 are growing;
- Almost all the products are close to last years level, with virtually 0 sales to Ukraine;
- Our «chemical» effort rewarded by 3-Quinuclidinol HCl entering top 15.






Growth Drivers: Countries

Ukraine Spoils the Party

- 13 out of 20 are growing, 7 main markets either growing or stable;
- Russia demonstrates 13% growth, despite high base;
- Among other best growers: US 34k%, Australia 7k%, Taiwan 600%, but also, UK +70%, Latvia +20%;
- Biggest reductions only at the end of the list, i.e. Uzbekistan, Canada, Spain, India, etc.







Update on Recent Events

Update for July & August

Preparing for the Leap

- Almost 71% purchased in Silvanols, a lot of emphasis on facilitating its exports. First news might come this year;
- Dividends paid on June 25th;
- In July unconsolidated sales down 9 %, 7 months on 7 months 4% growth, consolidated sales in July decreased by 5% to 3.9 million lats, 7 months consolidated sales demonstrate 5% growth.
- Due to significant recent Russian rouble fluctuations, price re-negotiations underway in Russia.



Sales and Profit Target Considerations Too Early to Call

- Sales target very close to plan (about 50% in 7 months);
- Profit target more behind schedule (32% in 6 months);
- Although minor, but growth has been achieved with Ukrainian sales virtually absent;
- In 2012 even less than a third of final net profit was achieved in first six months;
- The final outcome of bottomline will depend on development of Ukrainian sales.



In Focus: Sales to Ukraine

Much Depends on it

- Due to regolatory issues significant overshipment has been done in Q4 2012;
- According to estimates, products worth more than 3 million lats have been shipped in advance;
- Virtually no sales to Ukraine in February through May;
- For three months now Ukraine is back to normal sales levels of about 1 million EUR per month;
- Should the trend continue, management feels that it is realistic to meet sales and profit targets.







A Topic for Debate

A Stock-Split! How About That Now?

- One share of Olainfarm currently is one of the most expensive ones in Baltic Market;
- With everything else unchanged, after Latvia joins Euro zone, the share price will be slightly above 7 EUR, with expected further growth;
- Olainfarm has a broad retail investor base;
- Board is considering a tenfold stock split, leading to
 - 140 850 780 shares;
 - Face value of LVL 0,1 (EUR 0,14)
 - Market value (same conditions) of about 0,7 EUR
- What is your opinion?



Questions and Answers

Are always welcome

- In between webinars, please contact me at:
 - <u>Salvis.Lapins@olainfarm.lv</u>;
 - Cellular: +371 2 6448873;
 - Twitter: @SalvisLapins or @OlainFarm;



Thank you!

JSC Olainfarm

5 Rūpnīcu iela., Olaine, LV-2114, Latvia

Phone: +371 67013701 Fax: +371 67013777

www.olainfarm.lv

Investor relations:

Salvis Lapiņš, Member of the Board

Phone.: +371 26448873

e-mail: Salvis.Lapins@olainfarm.lv

